Clinical Trial Update: Venetoclax to Augment Epigenetic Modification and Chemotherapy [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating venetoclax to augment epigenetic modification and chemotherapy in relapsed or refractory acute myeloid leukemia; currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Venetoclax (venetoclax)

Snippet

Sponsor: Medical College of Wisconsin | Conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Phase 1 | Status: RECRUITING